Референции:
1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
2. FoundationOne®CDx Technical Specifications, 2020. Available at: https://www.foundationmedicine.com/test/foundationone-cdx (Accessed May 2021).
3. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-p170019 (Accessed May 2021).
4. FoundationOne® Liquid CDx Technical Specifications, 2020. Available at: https://www.foundationmedicine.com/test/foundationone-liquid-cdx (Accessed May 2021)
5. Woodhouse R et al. (2020) Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15(9): e0237802. September 25, 2020 Accessed at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237802 (Accessed May 2021).
6. FoundationOne Liquid CDx FDA Approval, 2020. Available at: https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed May 2021).
7. FoundationOne®Heme Technical Specifications, 2019. Available at: https://www.foundationmedicine.com/test/foundationone-heme (Accessed May 2021).
8. He J et al. Blood 2016; 127: 3004–3014.
9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
11. Ross JS et al. Cancer 2016; 122: 2654–2662.
12. Suh JH et al. Oncologist 2016; 21: 684–691.
13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
14. Foundation Insights. Available at: https://www.foundationmedicine.com/service/genomic-data-solutions (Accessed May 2021).